BioSyent logo.png
BioSyent Signs Exclusive Agreement for New Women’s Health Product
October 01, 2020 09:25 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Oct. 01, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that its subsidiary, BioSyent Pharma Inc., has signed an exclusive License...
BioSyent logo.png
BioSyent Releases Q2 and H1 2020 Results
August 26, 2020 07:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 26, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and six months ended June 30,...
BioSyent logo.png
BioSyent to Present at the LD 500 Virtual Conference
August 24, 2020 16:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 24, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced that it will be presenting at the LD 500 investor conference on...
BioSyent logo.png
BioSyent Schedules Q2 and H1 2020 Earnings Release for August 26, 2020
August 17, 2020 08:30 ET | BioSyent Inc.
MISSISSAUGA, Ontario, Aug. 17, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three and six months ended June 30,...
BioSyent logo.png
BioSyent Announces the Availability of Tibella® (tibolone) in Canada
July 29, 2020 16:01 ET | BioSyent Inc.
MISSISSAUGA, Ontario, July 29, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) today announced the Canadian launch and product availability of Tibella® (tibolone)...
BioSyent logo.png
BioSyent Releases Results for Q1 2020
May 28, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 28, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three months ended March 31, 2020. Key...
BioSyent logo.png
BioSyent Schedules Q1 2020 Earnings Release For May 28, 2020
May 21, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 21, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) will be reporting its financial results for the three months ended March 31, 2020 on...
BioSyent logo.png
FeraMAX® Named #1 Recommended Iron Supplement by National Pharmacists and Physicians for Fifth Consecutive Year
May 01, 2020 09:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, May 01, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) is pleased to announce that for the fifth consecutive year, FeraMAX® has been named the #1...
BioSyent logo.png
BIOSYENT ANNOUNCES GRANT OF RESTRICTED SHARE UNITS
March 31, 2020 19:41 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 31, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent” or the “Company”, TSX Venture: RX) announces that its Board of Directors has approved today a grant of 129,125...
BioSyent logo.png
BioSyent Releases Results for Fourth Quarter and Full Year 2019
March 18, 2020 08:00 ET | BioSyent Inc.
MISSISSAUGA, Ontario, March 18, 2020 (GLOBE NEWSWIRE) -- BioSyent Inc. (“BioSyent”, TSX Venture: RX) released today a summary of its financial results for the three and twelve months ended December...